Fatigue News and Research

RSS

Secret of building muscle using light weights

Current gym dogma holds that to build muscle size you need to lift heavy weights. However, a new study conducted at McMaster University has shown that a similar degree of muscle building can be achieved by using lighter weights. The secret is to pump iron until you reach muscle fatigue.

12 Aug 2010

VA Pittsburgh selects SmartSponge System to prevent retained surgical sponge incidents

ClearCount Medical Solutions and Medline Industries, Inc. today announced that its newest customer, the VA Pittsburgh Healthcare system will help prevent retained surgical sponge incidents with the use of the SmartSponge System®. The SmartSponge System is part of ClearCount's radio-frequency identification -based platform that uniquely identifies each sponge so that they can be easily counted and detected.

11 Aug 2010

Genmab reports top-line interim results from ofatumumab Phase II study in Diffuse Large B-Cell Lymphoma

Genmab A/S announced today top-line interim results from an initial Phase II single arm open label study of ofatumumab to evaluate the treatment of relapsed Diffuse Large B-Cell Lymphoma in patients ineligible for or relapsed following a stem cell transplant.

11 Aug 2010

Computerized warning system alerts harmful drug orders for older hospital patients

Adverse drug events, such as dizziness or confusion occur in an estimated 40 percent of all hospital patients and can be the result of inappropriate medications being ordered. Not surprisingly, elderly individuals are particularly vulnerable to these adverse events, which not only result in longer hospitalizations, but can also pose a threat of serious complications and even death.

10 Aug 2010

BioVentrix announces First-in-Man milestone for PliCath heart failure system

BioVentrix, developer of the PliCath HF™ System for use in Epicardial Catheter-based Ventricular Reconstruction (ECVR), today announced achievement of its First-in-Man milestone, performed on a 52-year-old male heart failure patient in Krakow, Poland. The PliCath HF System is designed to treat heart failure (HF) by reducing the enlarged Left Ventricle (LV) through an anchoring system that is delivered across the cardiac chambers with the use of a catheter.

9 Aug 2010

Chicago's mold count increases to 49,789, says allergist

Chicago's mold count is 49,789 - just a few spores away from the 50,000 threshold that signals a dangerous air quality warning. Today's mold count is the highest of the season, and the highest in five years. "Headaches, sinus congestion, runny noses and fatigue will be common among Chicagoans," says Dr Joseph Leija, allergist at Loyola's Gottlieb Memorial Hospital

7 Aug 2010

Hemispherx Biopharma second-quarter net loss decreases to $3.67 million

Hemispherx Biopharma, Inc. announced its financial results for the three months ended June 30, 2010. The net loss (including non-cash expenses) for the 2nd fiscal quarter was approximately $3,676,000 or $0.03 per share compared to a loss of approximately $3,870,000 or $0.04 per share for the same period in 2009.

7 Aug 2010

Recent releases in Global Health

According to a Lancet Comment, "alcohol remains conspicuously absent from the larger field of research and programming in HIV and substance use. ... Patterns of hazardous alcohol consumption prevail in countries with the most severe HIV epidemics, notably eastern and southern Africa." In addition, "hazardous drinking patterns also dominate in the concentrated epidemics of eastern Europe and Asia, where alcohol use by injecting drug users and other marginalised groups might be an additional barrier to effective efforts to prevent HIV infection."

7 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Phase I/II clinical study data of OncoVEXGM-CSF for head and neck cancer published in Clinical Cancer Research

BioVex Inc, a company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announces that the data from its completed Phase I/II clinical study of OncoVEXGM-CSF for the first line treatment of head and neck cancer is being published today in Clinical Cancer Research, an ASCO publication.

2 Aug 2010

Adequate recovery sleep duration important for coping with effects of chronic sleep restriction on the brain

A study in the Aug. 1 issue of the journal Sleep suggests that a dose of extra sleep on the weekend may be good medicine for adults who repeatedly stay up too late or wake up too early during the workweek. However, even a night of 10 hours in bed may not be enough to cure the negative effects of chronic sleep restriction.

2 Aug 2010

Intrinsic brain connectivity in fibromyalgia associated with chronic pain intensity

A recent study from researchers at Massachusetts General Hospital and University of Michigan provides the first direct evidence of linkage between elevated intrinsic (resting-state) brain connectivity and spontaneous pain intensity in patients with fibromyalgia (FM). This research shows an interaction of multiple brain networks, offering greater understanding of how pain arises. Details of the study appear online and in the August issue of Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology.

30 Jul 2010

Anthera initiates PEARL-SC Phase 2b study of A-623 for lupus

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it has initiated PEARL-SC, the Phase 2b study of A-623, a novel inhibitor of B-Cell Activating Factor, or BAFF, for the treatment of Systemic Lupus Erythematosus (lupus). Lupus patients suffer from a chronic autoimmune disease, which often leads to severe skin rash, fatigue, joint pain, major organ complications, and cardiovascular disease.

30 Jul 2010

Resting brain activity associated with spontaneous fibromyalgia pain

29 Jul 2010

AVEO second-quarter total revenues increase to $15.6 million

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an update on recent research and development (R&D) and business accomplishments, and announced financial results for the quarter ended June 30, 2010.

29 Jul 2010

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Allos Therapeutics, Inc. today announced topline results from the Company's randomized Phase 2b investigational trial of FOLOTYN® (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) who had received one or two prior systemic treatments including at least one prior platinum-based regimen. The objective of the trial was to estimate the efficacy of FOLOTYN compared to that of erlotinib as assessed by overall survival.

28 Jul 2010

Survey provides insight on roles, responsibilities for improved, sustainable workplace health

Employers should be active partners in the overall health of their employees and can play a strong role by encouraging them to take responsibility for their own health. While the thirteenth edition of The sanofi-aventis Healthcare Survey suggests that no employer or employee would dispute the return-on-investment from benefit plans such as prescription drugs, dental care, or employee assistance programs, improved and sustainable health in the workplace can only be achieved by a deeper commitment to early disease detection, preventative care, and wellness in general.

28 Jul 2010

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2010. The Company reported a net loss of $25.5 million, or $0.31 per share (basic and diluted), for the second quarter of 2010 compared with a net loss of $14.9 million, or $0.19 per share (basic and diluted), for the second quarter of 2009.

28 Jul 2010

CIHR grants $2.5 million to probe impact of physical activity on breast cancer

Over the next five years, a diverse, multi-disciplinary team of researchers led by Dr. Kerry Courneya of the University of Alberta and Dr. Christine Friedenreich of Alberta Health Services will conduct a series of five large research projects to probe the impacts of physical activity on breast cancer thanks to a $2.5 million team grant over five years from the Canadian Institutes of Health Research (CIHR).

28 Jul 2010

Need for better understanding of appropriate treatment choices for children with insomnia: Study

A new survey of child psychiatrists indicates that insomnia is a major problem among children in mental health treatment and at least a quarter of these patients are given sleep medication. The results of the survey, conducted by Judith Owens, MD, a sleep expert with Hasbro Children's Hospital, and colleagues, suggests that management of insomnia in this population is a common practice, although the clinical approach varies widely. The study is published in the August 2010 edition of Sleep Medicine.

27 Jul 2010

Fatigue News and Research

Secret of building muscle using light weights

VA Pittsburgh selects SmartSponge System to prevent retained surgical sponge incidents

Genmab reports top-line interim results from ofatumumab Phase II study in Diffuse Large B-Cell Lymphoma

Computerized warning system alerts harmful drug orders for older hospital patients

BioVentrix announces First-in-Man milestone for PliCath heart failure system

Chicago's mold count increases to 49,789, says allergist

Hemispherx Biopharma second-quarter net loss decreases to $3.67 million

Recent releases in Global Health

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Phase I/II clinical study data of OncoVEXGM-CSF for head and neck cancer published in Clinical Cancer Research

Adequate recovery sleep duration important for coping with effects of chronic sleep restriction on the brain

Intrinsic brain connectivity in fibromyalgia associated with chronic pain intensity

Anthera initiates PEARL-SC Phase 2b study of A-623 for lupus

Resting brain activity associated with spontaneous fibromyalgia pain

AVEO second-quarter total revenues increase to $15.6 million

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Survey provides insight on roles, responsibilities for improved, sustainable workplace health

Regeneron second-quarter total revenues increase to $115.9 million

CIHR grants $2.5 million to probe impact of physical activity on breast cancer

Need for better understanding of appropriate treatment choices for children with insomnia: Study

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News